Treatment of joint pain

Patent metadata

Field	Value
Publication number	US-10130628-B2
Application number	US-201715481129-A
Country	US
Kind code	B2
Filing date	Apr 6, 2017
Priority date	Jan 28, 2014
Publication date	Nov 20, 2018
Grant date	Nov 20, 2018

Abstract

This disclosure provides a technology for managing the sensation of pain in a subject in need thereof. Treatment methods according to this invention include administering to the subject a formulation that contains an effective amount of (4-[(4S,5R)-4,5-bis(4-chlorophenyl)-4,5-dihydro-2-[4-methoxy-2-(1-methylethoxy)phenyl]-1H-imidazol-1-yl]carbonyl]-2-piperazinone).

First claim

The invention claimed is:

1. A method for treating osteoarthritis, comprising administering to an osteoarthritic joint in a subject a pharmaceutical composition that contains a therapeutically effective amount of a senolytic agent defined as (4-[(4S,5R)-4,5 bis(4-chlorophenyl)-4,5-dihydro-2-[4-methoxy-2-(1-methylethoxy)phenyl]-1H-imidazol-1-yl]carbonyl]-2-piperazinone) (Nutlin-3A) or a salt thereof, in a pharmaceutically compatible excipient.

2. The method of claim 1 , wherein the senolytic agent is compounded in a sustained release formulation that comprises a gel, a polymeric matrix, or a microparticle.

3. The method of claim 1 , wherein the senolytic agent is administered to the osteoarthritic joint as a single dose, followed by a non-treatment interval of at least two weeks.

4. The method of claim 1 , wherein administration of the pharmaceutical composition inhibits erosion of a proteoglycan layer in the osteoarthritic joint.

5. The method of claim 1 , wherein administration of the pharmaceutical composition promotes production of collagen Type II in the osteoarthritic joint.

6. The method of claim 1 , wherein administration of the pharmaceutical composition relieves symptoms of osteoarthritis being experienced by the subject in the joint.

7. The method of claim 1 , wherein administration of the pharmaceutical composition relieves pain being experienced by the subject in the joint.

8. The method of claim 1 , wherein the senolytic agent is compounded in a formulation that includes a hyaluronan.

Assignees

• Unity Biotechnology Inc
• Buck Inst Res Aging
• Univ Johns Hopkins
• Mayo Found Medical Education & Res

Inventors

• David Nathaniel
• Davalos Albert
• Laberge Remi-Martin
• Campisi Judith
• Demaria Marco
• Vasserot Alain
• Kim Chaekyu
• Jeon Okhee
• Elisseeff Jennifer
• Kirkland James L
• Tchkonia Tamar
• Zhu Yi

Classifications

• A61K9/0073

  Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; (nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M) · CPC title

• A61K31/496 Primary

  Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin · CPC title

• A61K31/428

  condensed with carbocyclic rings · CPC title

• A61P19/02

  for joint disorders, e.g. arthritis, arthrosis · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title